Faeth Therapeutics (FTH) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$2.84

Estimate

-$4.76

Surprise

+40.3%

Score today

5.8/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Faeth Therapeutics (FTH) reported a narrower loss than forecast — diluted EPS of -$2.84 against the -$4.76 estimate (a 40.3% beat on a still-unprofitable quarter).

TrendMatrix currently rates FTH Sell at 5.8/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +40.3% surprise compares with a -5256.8% four-quarter average. Next scheduled report: 2026-11-03.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$37.44

Price target

$47.53

Stop

$34.82

Upside to target

+26.9%

Reward-to-risk

1.8:1

Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$967.5M

P/E (fwd)

-7.5

52-week range

$7.45–$42.14

Off 52-week high

11.2%

RSI (14)

62

Volume vs avg

1.20×

Score today

5.8/10